Acorda (ACOR) CEO On CNBC
More News related to ACOR
- Acorda Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
- Acorda Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Acorda Therapeutic (ACOR) volatility at 55 into extension of PDUFA
- Acorda Thera (ACOR) Posts Q3 Loss of $0.51, 8c Better than Estimates
- Acorda Therapeutics Reports Third Quarter 2009 Financial Results
More News related to BIIB
- Facet Biotech Advises Stockholders to Take No Action in Response to Revised Biogen Idec Tender Offer
- Biogen (BIIB) Boosts Bid for Facet Biotech (FACT) to $17.50/Share in Cash
- Biogen Idec Increases Offer to Acquire Facet Biotech to $17.50 Per Share in Cash; Sends Letter to Facet Biotech Stockholders Describing Its Best-and-Final Offer
- InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc.
- Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
Acorda Therapeutics, Inc. (Nasdaq: ACOR) CEO Ron Cohen is speaking on CNBC now about this morning's deal with Biogen Idec (Nasdaq: BIIB) to commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
While the stock is down 11.6% on the news, Cohen calls it a "great deal."
CNBC reporter Mike Huckman suggests there may be some disappointment that it wasn't a buyout, about the terms of the deal, or are selling after the recent run-up. Cohen said he can't explain the stock reaction to the news.
Related Categories
FDAStocks Mentioned
-0.74Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
